Osiris Therapeutics Inc.
) reported a second-quarter 2013 loss of 11 cents per share, a
couple of cents wider than the Zacks Consensus Estimate but
narrower than the year-ago loss of 13 cents per share. Revenues
for the quarter came in at $5.4 million, above the Zacks
Consensus Estimate of $4.0 million and the year-ago quarter
revenues of $1.7 million.
Biosurgery product revenues came in at $5.3 million, up 231%
from the year-ago period.
Research and development (R&D) expenses declined 19.5%
from the year-ago period to $3.3 million. Selling, general and
administrative expenses increased 214.3% from the year-ago period
to $4.4 million due to higher commercial activities in the
Osiris has made significant progress with stem cell therapies.
The upside potential to lead candidate Prochymal could be
enormous. Prochymal gained approval in Canada and New Zealand in
the second quarter of 2012 for the treatment of acute
graft-versus-host disease (GvHD) in children. Prochymal is the
first manufactured stem cell product to gain approval and the
first treatment to gain approval for GvHD.
Osiris is studying Prochymal for several indications including
Crohn's disease and acute myocardial infarction, which are
The company is looking for a partner for Prochymal. Last year,
Osiris had regained commercial rights for Prochymal and
Osiris currently carries a Zacks Rank #3 (Hold). At present,
Anika Therapeutics, Inc.
) look well-positioned with both being Zacks Rank #1 (Strong Buy)
ACTELION LTD (ALIOF): Get Free Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis
OSIRIS THERAPTC (OSIR): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.